A comparative study of mesenchymal stem cell transplantation with its paracrine effect on control of hyperglycemia in type 1 diabetic rats

被引：20
作者：
Aali E. [1 ]
Mirzamohammadi S. [1 ]
Ghaznavi H. [1 ]
Madjd Z. [4 ]
Larijani B. [3 ]
Rayegan S. [1 ]
Sharifi A.M. [1 ,2 ,3 ]
机构：
[1] Razi Drug Research Center, Department of Pharmacology, Iran University of Medical Sciences, Tehran
[2] Department of Tissue Engineering and Cell Therapy, School of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran
[3] Endocrine and Metabolism Research Institute, Shariati Hospital, Tehran University of Medical Sciences, Tehran
[4] Oncopathology Research Center, Department of Pathology, Iran University of Medical Sciences, Tehran
来源：
Journal of Diabetes & Metabolic Disorders | / 13卷 / 1期
关键词：
Diabetes mellitus; Hyperglycemia; Mesenchymal stem cells;
D O I：
10.1186/2251-6581-13-76
中图分类号：
学科分类号：
摘要：
Background: Many studies suggested mesenchymal stem cells (MSCs) transplantation as a new approach to control hyperglycemia in type 1 diabetes mellitus through differentiation mechanism. In contrary others believed that therapeutic properties of MSCs is depends on paracrine mechanisms even if they were not engrafted. This study aimed to compare these two approaches in control of hyperglycemia in STZ-induced diabetic rats.Methods: Animals were divided into five groups: normal; diabetic control; diabetic received MSCs; diabetic received supernatant of MSCs; diabetic received co-administration of MSCs with supernatant. Blood glucose, insulin levels and body weight of animals were monitored during experiment. Immunohistochemical and immunofluorescence analysis were performed to monitor functionality and migration of labeled-MSCs to pancreas.Results: First administration of MSCs within the first 3 weeks could not reduce blood glucose, but second administration significantly reduced blood glucose after week four compared to diabetic controls. Daily injection of supernatant could not reduce blood glucose as efficient as MSCs. Interestingly; Co-administration of MSCs with supernatant significantly reduced blood glucose more than other treated groups. Insulin levels and body weight were significantly increased in MSCs + supernatant-treated animals compared to other groups. Immunohistological analysis showed an increase in number and size of islets per section respectively in supernatant, MSCs and MSCs + supernatant-treated groups.Conclusion: Present study exhibited that repeated-injection of MSCs reduced blood glucose and increased serum insulin levels in recipient rats. Injection of supernatant could not reverse hyperglycemia as efficient as MSCs. Interestingly; co-administration of MSCs with supernatant could reverse hyperglycemia more than either group alone. © 2014 Aali et al.; licensee BioMed Central Ltd.
引用
收藏
相关论文
共 39 条
  • [31] Block G.J., Ohkouchi S., Fung F., Frenkel J., Gregory C., Pochampally R., Multipotent stromal cells are activated to reduce apoptosis in part by upregulation and secretion of stanniocalcin-1, Stem Cells, 27, 3, pp. 670-681, (2009)
  • [32] Martinet L., Fleury-Cappellesso S., Gadelorge M., Dietrich G., Bourin P., Fournie J.J., Poupot R., A regulatory cross-talk between Vgamma9Vdelta2 T lymphocytes and mesenchymal stem cells, Eur J Immunol, 39, 3, pp. 752-762, (2009)
  • [33] Baddoo M., Hill K., Wilkinson R., Gaupp D., Hughes C., Kopen G.C., Phinney D.G., Characterization of mesenchymal stem cells isolated from murine bone marrow by negative selection, J Cell Biochem, 89, pp. 1235-1249, (2003)
  • [34] Ezquer F.E., Ezquer M.E., Parrau D.B., Carpio D., Yanez A.J., Conget P.A., Systemic administration of multipotent mesenchymal stromal cells reverts hyperglycemia and prevents nephropathy in type 1 diabetic mice, Biol Blood Marrow Transplant, 14, pp. 631-640, (2008)
  • [35] Miryounesi M., Piryaei A., Pournasr B., Aghdami N., Baharvand H., Repeated versus single transplantation of mesenchymal stem cells in carbon tetrachloride-induced liver injury in mice, Cell Biol Int, 10, (2013)
  • [36] Lee S.R., Lee S.H., Moon J.Y., Park J.Y., Lee D., Lim S.J., Jeong K.H., Park J.K., Lee T.W., Ihm C.G., Repeated administration of bone marrow-derived mesenchymal stem cells improved the protective effects on a remnant kidney model, Renal Failure, 32, 7, pp. 840-848, (2010)
  • [37] Furuichi K., Shintani H., Sakai Y., Ochiya T., Matsushima K., Kaneko S., Wada T., Effects of adipose-derived mesenchymal cells on ischemia-reperfusion injury in kidney, Clin Exp Nephrol, 16, 5, pp. 679-689, (2012)
  • [38] Bi B., Schmitt R., Israilova M., Nishio H., Cantley L.G., Stromal cells protect against acute tubular injury via an endocrine effect, J Am Soc Nephrol, 18, 9, pp. 2486-2496, (2007)
  • [39] Timmers L., Lim S.K., Hoefer I.E., Arslan F., Lai R.C., van Oorschot A.A., Goumans M.J., Strijder C., Sze S.K., Choo A., Piek J.J., Doevendans P.A., Pasterkamp G., de Kleijn D.P., Human mesenchymal stem cell-conditioned medium improves cardiac function following myocardial infarction, Stem Cell Res, 6, pp. 206-214, (2011)
1234